Jennifer Doudna, AP Images

Hit­ting land­mark mile­stone, In­tel­lia shows CRISPR can ed­it genes di­rect­ly in pa­tients

In a land­mark study, re­searchers suc­cess­ful­ly used CRISPR to di­rect­ly ed­it DNA in hu­mans, a mile­stone that could pave the way for treat­ments for scores of se­ri­ous ge­net­ic and non-ge­net­ic dis­eases.

In­tel­lia, a biotech co-found­ed by 2020 No­bel lau­re­ate Jen­nifer Doud­na, used CRISPR/Cas9 to cut a gene out of the liv­er cells of pa­tients with AT­TR amy­loi­do­sis, a dead­ly dis­ease where a mis­shapen pro­tein called TTR builds up and dam­ages or­gans through­out the body. Pa­tients who re­ceived a high dose of the ther­a­py saw their pro­tein lev­els fall be­tween 80% and 96%, in­di­cat­ing the ther­a­py per­ma­nent­ly cut the genome where de­sired.

The Phase I re­sults were pub­lished Sat­ur­day in the New Eng­land Jour­nal of Med­i­cine and pre­sent­ed at a sci­en­tif­ic con­fer­ence.

“This is the re­sult that the field has been wait­ing for to re­al­ly scale up,” Fy­o­dor Urnov, a gene edit­ing ex­pert at UC Berke­ley who was not af­fil­i­at­ed with the work, told End­points News. “If any­one had a shred of doubt, that there was a fu­ture in CRISPR edit­ing as a ther­a­peu­tic that will have a broad im­pact, those doubts can be put to rest.”

This is not the first time CRISPR has been used as a ther­a­py. Ver­tex and CRISPR Ther­a­peu­tics have used it to ef­fec­tive­ly treat sick­le cell dis­ease and be­ta-tha­lassemia. Aca­d­e­mics and oth­er com­pa­nies have, with some­what less suc­cess, used it in treat­ments for can­cer and HIV. But in each case, re­searchers re­moved blood stem cells from the pa­tients, edit­ed them in a lab and then re­turned them to the pa­tient — a sim­pler, safer and more con­trol­lable pro­ce­dure.

Most con­di­tions, though, can’t be ad­dressed by edit­ing cells out­side the body. Dev­as­tat­ing ge­net­ic dis­eases such as cys­tic fi­bro­sis and Duchenne mus­cu­lar dy­s­tro­phy could be treat­ed through CRISPR gene edit­ing, but on­ly if re­searchers can de­liv­er the ther­a­py di­rect­ly in­to pa­tients. The same holds true for some of the more com­mon ail­ments where com­pa­nies are now try­ing to ap­ply the tech­nol­o­gy, such as heart dis­ease.

On Sat­ur­day, In­tel­lia be­came the first to pull it off. Doud­na hailed it as a proof-of-con­cept for the en­tire field.

“While these are ear­ly da­ta, they show us that we can over­come one of the biggest chal­lenges with ap­ply­ing CRISPR clin­i­cal­ly so far, which is be­ing able to de­liv­er it sys­tem­i­cal­ly and get it to the right place,” Doud­na said in an email. “It’s a crit­i­cal first step in be­ing able to in­ac­ti­vate, re­pair or re­place any gene that caus­es dis­ease, any­where in the body. This opens up the pos­si­bil­i­ty to treat a wide range of dis­eases that we haven’t been able to ad­dress so far.”

In­tel­lia’s stock $NT­LA jumped 52% when pre-mar­ket trad­ing be­gan Mon­day, rais­ing their mar­ket cap by $3 bil­lion. The oth­er so-called “CRISPR com­pa­nies,” in­clud­ing Beam, CRISPR Ther­a­peu­tics, and Ed­i­tas, all rose be­tween 15% and 25%.

In­tel­lia be­gan work­ing on the AT­TR pro­gram not long af­ter it was found­ed in 2014, said CEO John Leonard. They tin­kered for years, af­ter the first ver­sions edit­ed less than 2% of tar­get­ed cells in mice. Even­tu­al­ly, they de­vised two RNA strands, one that codes for the DNA-cut­ting en­zyme Cas9 and an­oth­er, the guide RNA, that tells Cas9 which gene to cut.

Lau­ra Sepp-Loren­zi­no

They en­cased the RNA in a lipid nanopar­ti­cle, the mi­cro­scop­ic bub­bles of fat that have now been used around the world to de­liv­er mR­NA Covid-19 vac­cines. Af­ter the LNPs are ad­min­is­tered to pa­tients, they go to the liv­er, ex­press Cas9, which slices the DNA, and flush out with­in hours, said CSO Lau­ra Sepp Loren­zi­no.

“Part of our de­sign cri­te­ria was rapid elim­i­na­tion,” Loren­zi­no told End­points.

The first three AT­TR pa­tients, who re­ceived a low dose of the ther­a­py, saw their pro­duc­tion of TTR pro­tein fall by an av­er­age of 57%. When they es­ca­lat­ed for the next three pa­tients, they saw an av­er­age re­duc­tion of 87%.

The lat­ter fig­ure close­ly ri­vals the da­ta from Al­ny­lam’s RNAi drug On­pat­tro, one of three drugs re­cent­ly ap­proved for the dis­ease. But In­tel­lia’s ap­proach on­ly has to be dosed once in a life­time, as op­posed to once every three weeks.

“The lev­el of TTR pro­tein re­duc­tion is im­pres­sive,” Har­vard bio­chemist David Liu, who co-found­ed CRISPR com­pa­nies Beam and Prime, said in an email. The da­ta “serve as a com­pelling re­minder that the era of in vi­vo ther­a­peu­tic hu­man gene edit­ing is al­ready up­on us.”

David Liu

Liu not­ed In­tel­lia got re­sults de­spite us­ing less than 1/10th the dose they used in mon­keys. The com­pa­ny plans to up the dosage fur­ther to try to com­plete­ly elim­i­nate pro­tein pro­duc­tion — a bench­mark they hope will not on­ly stop the dis­ease’s pro­gres­sion but po­ten­tial­ly re­verse it, giv­ing the body time to clean up that mis­shapen pro­tein that ac­cu­mu­lat­ed in the years pri­or to ther­a­py.

Out­side ex­perts took par­tic­u­lar note of the safe­ty da­ta. It was not clear what would hap­pen when re­searchers first ad­min­is­tered Cas9, a pro­tein de­rived from bac­te­ria, through­out the body. Some feared that the im­mune sys­tem would rec­og­nize it as for­eign and go in­to dan­ger­ous over­drive.

“The safe­ty da­ta look re­al­ly good,” Alex­is Ko­mor, who runs a gene edit­ing lab at UC San Diego, told End­points. “There’s no crazy im­mune re­sponse. That was a ques­tion that every­body’s had for a while.”

Alex­is Ko­mor

Still, there are key safe­ty ques­tions that can on­ly be an­swered with time. Over the last decade, CRISPR re­searchers have doc­u­ment­ed in nu­mer­ous lab stud­ies that, by break­ing the DNA in two, Cas9 can in­flict un­in­tend­ed dam­age on the genome.

So far those have not born out in pa­tients and ex­perts say there are no red flags in In­tel­lia’s da­ta. But it will be hard­er for In­tel­lia to mon­i­tor than for pre­vi­ous com­pa­nies who edit­ed blood cells; they were able to check in the lab how the cells re­spond­ed ini­tial­ly and take sub­se­quent sam­ples from pa­tients to mon­i­tor.

By con­trast, doc­tors can’t just re­move a pa­tient’s liv­er to mon­i­tor for ear­ly signs of can­cer. “There’s just a fun­da­men­tal ques­tion of how we do long-term fol­lowup,” Urnov said.

The com­pa­ny will now look to ap­ply the same strat­e­gy they used for AT­TR to an­oth­er ge­net­ic dis­ease, hered­i­tary an­gioede­ma, swap­ping out the guide RNA for TTR and re­plac­ing it with one for a gene called KLB1.

Fy­o­dor Urnov

Urnov said the tech­nol­o­gy will work like mR­NA vac­cines: Once proven, the plat­form can be re­de­ployed for an­oth­er dis­ease by swap­ping out one set of ge­net­ic in­struc­tions for an­oth­er. It pro­vides a proof of prin­ci­ple for Verve Ther­a­peu­tics, which is try­ing to pre­vent heart dis­ease by knock­ing out a gene in the liv­er that strong­ly af­fects cho­les­terol lev­els.

For these com­pa­nies, he said, “the ball is in your court,” he said, “to do it and just not drop the ball.”

But that on­ly ap­plies to a sub­set of ther­a­pies and dis­eases. In­tel­lia ef­fec­tive­ly went af­ter the low­est hang­ing fruit for sys­temic CRISPR treat­ments. They di­rect­ed the treat­ment against the liv­er, the body’s in­ter­nal fil­ter and the eas­i­est or­gan to di­rect ge­net­ic ther­a­pies. And they on­ly tried to crip­ple a gene, rather than re­pair one.

To tack­le most of the dis­eases sci­en­tists en­vi­sioned cur­ing when CRISPR was first pi­o­neered a decade ago, re­searchers will have to prove they can de­liv­er through­out the body and, once there, turn a mu­tant gene in­to a healthy one — a pair of sig­nif­i­cant­ly high­er hur­dles.

Rodolphe Bar­ran­gou

Ear­ly tests for those hur­dles will ar­rive in the com­ing years, as ther­a­pies for Duchenne and HIV, among oth­ers, en­ter the clin­ic.

“It’s an ex­cit­ing day, it’s an ex­cit­ing mile­stone,” Rodolphe Bar­ran­gou, an ear­ly CRISPR re­searcher and a co-founder of In­tel­lia, told End­points. “But we have a ways to go.”

Biotech in­vestors and CEOs see two paths to growth, but are they equal­ly vi­able?

The dynamic in the biotech market has been highly volatile in the last few years, from the high peaks immediately after the COVID vaccine in 2021, to the lowest downturns of the last 20 years in 2022. This uncertainty makes calling the exact timing of the market’s turn something of a fool’s errand, according to Dr. Chen Yu, Founder and Managing Partner of TCG Crossover (TCG X). He speaks with RBC’s Noël Brown, Head of US Biotechnology Investment Banking, about the market’s road ahead and two possible paths for growth.

Casey McPherson shows his daughters Rose (left) and Weston around Everlum Bio, a lab that he co-founded to spark a treatment for Rose and others with ultra-rare conditions. (Ilana Panich-Linsman)

Fa­ther starts lab af­ter in­tel­lec­tu­al prop­er­ty is­sues stymie rare dis­ease drug de­vel­op­ment

Under bright lab lights, Casey McPherson holds his 6-year-old daughter, Rose. His free hand directs Rose’s gaze toward a computer screen with potential clues in treating her one-of-a kind genetic condition.

Gray specks on the screen show her cells that scientists reprogrammed with the goal of zeroing in on a custom medicine. McPherson co-founded the lab, Everlum Bio, to spark a treatment for Rose — and others like her. A regarded singer-songwriter, McPherson never imagined going into drug development.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Fireside chat between Hal Barron and John Carroll, UKBIO19

It’s time we talked about bio­phar­ma — live in Lon­don next week

Zoom can only go so far. And I think at this stage, we’ve all tested the limits of staying in touch — virtually. So I’m particularly happy now that we’ve revved up the travel machine to point myself to London for the first time in several years.

Whatever events we have lined up, we’ve always built in plenty of opportunities for all of us to get together and talk. For London, live, I plan to be right out front, meeting with and chatting with the small crowd of biopharma people we are hosting on October 12 at Silicon Valley Bank’s London headquarters. And there’s a lengthy mixer at the end I’m most looking forward to, with several networking openings between sessions.

Take­da to pull key hy­poparathy­roidism drug from the mar­ket af­ter years of man­u­fac­tur­ing woes

Takeda on Tuesday morning made an announcement that almost 3,000 people with the rare disease known as hypoparathyroidism were fearing.

Due to unresolved supply issues and manufacturing woes, Takeda said it will cut its losses and discontinue its hypoparathyroidism drug, known as Natpara (parathyroid hormone), halting all manufacturing of the drug by the end of 2024, but the entire inventory will be available until depleted or expired, a company spokesperson said via email.

Tim Miller, Forge Biologics CEO

CNS-fo­cused gene ther­a­py biotech forges man­u­fac­tur­ing deal for hear­ing loss drug

A growing gene therapy company is teaming up with one of the largest gene therapy manufacturers to get its drug into patients in clinical trials.

Myrtelle announced on Monday that it inked a deal with Forge Biologics to make Myr-201, a gene therapy indicated for monogenic hearing loss. The target patient population, Myrtelle said, is people with a type of hearing loss called DFNB8, or autosomal recessive deafness 8.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Pfizer and BioNTech's original Marvel comic book links evolving Covid vaccine science to Avengers' evolving villain-fighting tools.(Source: Pfizer LinkedIn post)

Pfiz­er, BioN­Tech part­ner with Mar­vel for Avengers and Covid-fight­ing com­ic book

Pfizer and BioNTech are collaborating with Marvel to celebrate “everyday” people getting Covid-19 vaccines in a custom comic book.

In the “Everyday Heroes” digital comic book, an evolving Ultron, one of the Avengers’ leading villains, is defeated by Captain America, Ironman and others. The plotline and history of Ultron is explained by a grandfather who is waiting with his family at a clinic for Covid-19 vaccinations.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Kaile Zagger, Infinant Health CEO

UC Davis mi­cro­bio­me spin­out re­brands in­fant sup­ple­ment busi­ness with na­ture fo­cus

When Kaile Zagger took the helm of UC Davis spinout Evolve Biosystems several months ago, the company billed itself as a probiotic maker.

However, she believes the company’s Evivo supplement designed to help infants develop a healthy gut microbiome is “so much more” — and that, she said, calls for a rebrand.

Evolve has, well, evolved into Infinant Health, the company announced on Monday. The new name is a mash-up of the words “infant” and “infinite,” representing the company’s goal of expanding beyond infant care. While its sole product, Evivo, is intended for newborns, Infinant is “quickly developing” an option for kids through the age of two.

FDA+ roundup: Ad­comm date set for Cy­to­ki­net­ics heart drug; New gener­ic drug guid­ance to re­duce fa­cil­i­ty de­lays

The FDA on Wednesday set Dec. 13 as the day that its Cardiovascular and Renal Drugs Advisory Committee will review Cytokinetics’ potential heart drug, meaning regulators aren’t likely to meet the Nov. 30 PDUFA date that was previously set.

The drug, known as omecamtiv mecarbil, read out its first Phase III in November 2020, hitting the primary endpoint of reducing the odds of hospitalization or other urgent care for heart failure by 8%. But it also missed a key secondary endpoint analysts had pegged as the key to breaking into the market, failing to significantly differ in reducing cardiovascular death from placebo.

Endpoints News

Keep reading Endpoints with a free subscription

Unlock this story instantly and join 150,500+ biopharma pros reading Endpoints daily — and it's free.

Bob Azelby, Eliem Therapeutics CEO

Eliem says ear­li­er drug ex­po­sure is­sues have been re­solved, drops one epilep­sy in­di­ca­tion

After being forced to delay two Phase IIa trials and blaming CMC issues on a Phase Ib miss, Eliem Therapeutics believes it’s now in the clear.

The Seattle and UK-based biotech put out word Wednesday morning about how it conducted new early-stage studies to confirm why low exposure issues arose during the Phase Ib. After researchers compared the results of the studies, Eliem found “no meaningful difference” between them and ruled out CMC as the reason for the foiled Phase Ib study, the company said in a press release.